Chai Phua: 1st Publicly Funded Hemgenix Treatment for Hemophilia B in Canada Marks Historic Gene Therapy Milestone
Chai Phua, Associate Professor at Schulich School of Medicine and Dentistry, shared on LinkedIn:
”A historic milestone for bleeding disorders care in Canada.
Last week, the first publicly funded Canadian patient received Hemgenix for Hemophilia B at London Health Sciences Centre.
While this moment represents a major step forward in gene therapy and hemophilia B care, it also reflects decades of foundational work by leaders, clinicians, researchers, nurses, hemostasis laboratories, blood banks, patient advocates, and the broader bleeding disorders community across Canada who helped build the systems, expertise, and advocacy needed to make innovative therapies like this possible.
Most importantly, this milestone represents hope not only for one patient, but for the future of innovative therapies in rare diseases across Canada.
Thank you to everyone who helped make this possible.”
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal